Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis by Cooper, Katy L et al.
RESEARCH ARTICLE Open Access
Granulocyte colony-stimulating factors for febrile
neutropenia prophylaxis following chemotherapy:
systematic review and meta-analysis
Katy L Cooper
1*, Jason Madan
2, Sophie Whyte
1, Matt D Stevenson
1 and Ron L Akehurst
1
Abstract
Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with
morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G-
CSFs) stimulate neutrophil production and may reduce FN incidence when given prophylactically following
chemotherapy.
Methods: A systematic review and meta-analysis assessed the effectiveness of G-CSFs (pegfilgrastim, filgrastim or
lenograstim) in reducing FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. G-CSFs
were compared with no primary G-CSF prophylaxis and with one another. Nine databases were searched in
December 2009. Meta-analysis used a random effects model due to heterogeneity.
Results: Twenty studies compared primary G-CSF prophylaxis with no primary G-CSF prophylaxis: five studies of
pegfilgrastim; ten of filgrastim; and five of lenograstim. All three G-CSFs significantly reduced FN incidence, with
relative risks of 0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95%
CI: 0.44 to 0.88) for lenograstim. Overall, the relative risk of FN for any primary G-CSF prophylaxis versus no primary
G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62). In terms of comparisons between different G-CSFs, five studies
compared pegfilgrastim with filgrastim. FN incidence was significantly lower for pegfilgrastim than filgrastim, with a
relative risk of 0.66 (95% CI: 0.44 to 0.98).
Conclusions: Primary prophylaxis with G-CSFs significantly reduces FN incidence in adults undergoing
chemotherapy for solid tumours or lymphoma. Pegfilgrastim reduces FN incidence to a significantly greater extent
than filgrastim.
Background
Neutropenia is the major dose-limiting toxicity of many
chemotherapy regimens. Grade 3 and grade 4 neutrope-
nia are defined as a neutrophil count < 1.0 × 10
9/L and
<0 . 5×1 0
9/L respectively. Febrile neutropenia (FN) is
defined as neutropenia with fever, usually indicating
infection, and is associated with substantial morbidity,
mortality, and costs [1]. The direct risk of mortality
associated with FN has been estimated as 9.5% (95%
confidence interval [CI]: 9.2%, 9.8%) in a study of 41,779
cancer patients hospitalised with FN [1]. Management
of FN often requires lengthy hospitalisation, [1] with
associated costs and detrimental effects on quality of
life [2,3]. In addition, an FN episode has been shown to
increase the risk of chemotherapy dose reductions and
delays [4]. Unplanned reductions in chemotherapy dose
may cause further deaths from cancer in the long-term;
in a retrospective analysis of breast cancer patients with
a 30-year follow-up, the survival rate was 40% (95% CI:
26%, 55%) among patients receiving at least 85% of their
planned dose, but only 21% (95% CI: 14%, 26%) among
patients who received less than 85% [5].
Recombinant human granulocyte colony-stimulating
factors (G-CSFs) stimulate production of mature, func-
t i o n a ln e u t r o p h i l s[ 6 ] .G - C S F sh a v eb e e ns h o w nt o
reduce the incidence of FN when used as prophylaxis
following chemotherapy. Three G-CSFs are currently in
common usage: filgrastim, pegfilgrastim, and
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any medium, provided the original work is properly cited.lenograstim. Filgrastim and lenograstim are administered
as a series of daily injections; clinical studies suggest an
average of 11 injections per chemotherapy cycle are
required to achieve recovery of the absolute neutrophil
count (ANC) to within the normal range [7-10]. Pegfil-
grastim is administered as a single injection per che-
motherapy cycle [11,12]. G-CSFs may be administered
as primary prophylaxis (in every chemotherapy cycle
from cycle 1) or as secondary prophylaxis (in all remain-
ing cycles following a neutropenic event such as FN or
prolonged severe neutropenia). The overall FN risk is
dependent on chemotherapy regimen as well as indivi-
dual patient risk factors such as age, performance status
and disease stage [13]. Guidelines from the European
Organisation for Research and Treatment of Cancer
(EORTC), [13] the American Society of Clinical Oncol-
ogy (ASCO) [14] and the National Comprehensive Can-
cer Network (NCCN) [15] recommend that prophylactic
G-CSFs should be used where the risk of FN associated
with the chemotherapy regimen is greater than or equal
to 20%, and may be considered where the risk is 10-
20%, particularly where additional patient risk factors
are present.
This paper reports a systematic review and meta-ana-
lysis of the effect of primary G-CSF prophylaxis (with
pegfilgrastim, filgrastim or lenograstim) on incidence of
FN. The effect of each G-CSF is assessed in comparison
with no primary G-CSF prophylaxis and in comparison
with other G-CSFs.
Methods
Search strategy
The systematic review followed the recommendations in
the PRISMA statement [16,17]. A systematic search was
undertaken to identify randomised controlled trials
(RCTs) of pegfilgrastim, filgrastim or lenograstim, com-
pared with no primary G-CSF or with one another, for
the reduction of FN following chemotherapy. A previous
systematic review by Kuderer et al. [18] presented a
meta-analysis of FN incidence within RCTs of primary
G-CSF prophylaxis versus no primary G-CSF prophy-
laxis, while a systematic review by Pinto et al. [19]
meta-analysed RCTs of primary prophylaxis using pegfil-
grastim versus filgrastim. The literature searches within
these previous reviews were conducted during 2006.
Therefore, databases were searched from 2006 onwards,
whereas studies published prior to 2006 were identified
from the two existing reviews. Searches were undertaken
in December 2009. The following databases were
searched: Medline, Medline in Process, EMBASE,
Science Citation Index, Cochrane Database of Systema-
tic Reviews, Cochrane CENTRAL Register of Controlled
Trials, Database of Abstracts of Reviews of Effects
(DARE), Health Technology Assessment Database and
NHS Economic Evaluation Database (NHS-EED). The
Medline search strategy was designed with reference to
the previous two reviews, and comprised subject head-
ings and text words for G-CSFs combined with a search
filter to identify RCTs (Appendix 1). Searches were not
restricted by language. Bibliographies of retrieved papers
were searched for any additional relevant studies.
Inclusion and exclusion criteria
Studies were considered suitable for inclusion if they
assessed primary G-CSF prophylaxis (pegfilgrastim, fil-
grastim or lenograstim) administered 1-3 days after the
completion of chemotherapy, versus a different G-CSF
or versus no primary G-CSF prophylaxis. Studies were
only included if they reported incidence of FN. For con-
sistency with the two existing systematic reviews, [18,19]
only studies of adult cancer patients with solid tumours
or lymphoma were included. Studies allowing concomi-
tant antibiotic prophylaxis were included if identical
prophylaxis was administered in both study arms. The
following study types were excluded: studies of G-CSFs
for treatment of FN; studies in children; studies in
patients with leukaemia, myeloid malignancies or myelo-
dysplastic syndromes; studies of G-CSFs for stem cell
mobilisation in bone marrow or peripheral blood stem
cell transplantation; economic analyses; studies with dif-
fering drugs, doses or schedules of chemotherapy in
each arm; studies with differing doses of the same G-
CSF in each arm; and studies not published in English.
Outcome measures
The outcome measure assessed in this review was the
incidence of FN over all cycles of chemotherapy within
each study. FN was chosen as a key clinical outcome
due to its direct bearing on morbidity, mortality and
hospitalisation rates, and also because this review was
undertaken alongside the development of an economic
model which utilised FN rate as a key parameter.
Data extraction
Data was extracted by two reviewers using a form devel-
oped for this review and any discrepancies were resolved
through discussion.
Data synthesis
Meta-analyses were undertaken to compare the effec-
tiveness of G-CSFs versus no prophylaxis and versus
each other for the reduction of FN. Analyses were
undertaken using RevMan software (version 5, Cochrane
Collaboration). Results for each comparison were pre-
sented as a pooled relative risk and 95% CIs. Although
clinical and statistical heterogeneity existed between stu-
dies, there was insufficient data on individual popula-
tions to facilitate separate analyses. Therefore, for
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included in the analysis, and a random effects model
was used. Heterogeneity was presented using the I
2 sta-
tistic, which describes the percentage of the variability
in effect estimates that is due to heterogeneity rather
than sampling error (chance) [20].
Results
Number and characteristics of included studies
The flow chart for study inclusion is shown in Figure 1
and the included studies are described in Table 1. Stu-
dies published from 2006 onwards were identified from
the literature search, and studies published prior to
2006 were identified from two previous reviews [18,19].
In total, 23 citations relating to 25 studies satisfied the
inclusion criteria: 5 studies of primary pegfilgrastim vs.
no primary G-CSF (within 4 citations); [21-24] 10 stu-
dies of primary filgrastim vs. no primary G-CSF (within
9 citations); [25-33] 5 studies of primary lenograstim vs.
no primary G-CSF; [9,10,34-36] and 5 studies of primary
pegfilgrastim vs. primary filgrastim [7,8,37-39]. No stu-
dies were identified comparing lenograstim with either
pegfilgrastim alone or filgrastim alone.
A previous systematic review of prophylactic G-CSF
use [18] included only a single study of pegfilgrastim
versus no primary G-CSF [21]. Our literature search
identified 4 additional RCTs of pegfilgrastim vs. no pri-
mary G-CSF, which were conducted in populations with
colorectal cancer, [24] breast cancer, [23] non-Hodgkin’s
lymphoma, [22] and various solid tumours; [22] the lat-
ter three studies were restricted to elderly patients. Our
review also identified an additional large RCT of filgras-
tim vs. no primary G-CSF in breast cancer [33].
There was heterogeneity among trials of all three G-
CSFs in terms of cancer type, patient age, chemotherapy
regimen, number of chemotherapy cycles and cycle
length (Table 1). Filgrastim and lenograstim were gener-
ally given for 10-14 days where the chemotherapy cycle
length was 3 weeks (and for fewer days in a small num-
ber of trials with shorter cycle lengths). The comparator
arm in some of the studies included secondary G-CSFs
for those patients having an FN event, and some trials
allowed prophylactic antibiotics in both arms. Some stu-
dies were open-label rather than double-blind.
Effectiveness of G-CSFs in reducing febrile neutropenia
incidence
The relative risks of FN incidence are shown in Figure 2
for trials of G-CSF versus no primary G-CSF, and in
Figure 3 for trials of pegfilgrastim versus filgrastim. The
pooled relative risks for each G-CSF comparison are
summarised in Table 2. Primary prophylaxis with each
of the G-CSFs significantly decreased the risk of FN
compared with no primary G-CSF, with relative risks of
0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95%
CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to
0.88) for lenograstim. Overall, the relative risk of FN
when using any primary G-CS Fp r o p h y l a x i sv e r s u sn o
primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to
0.62).
There was a relatively high level of statistical heteroge-
neity in the analyses as shown by the I
2 statistic, which
ranged from 50-76%; this is likely to reflect the varia-
tions between studies in factors such as cancer type,
patient age, chemotherapy regimen, number of che-
motherapy cycles and cycle length. Individual studies
differed on too many variables for formal sub-analyses
to be meaningful. However, Figures 2 and 3 illustrate
the cancer type for each study (shown after the author
and date) and highlight studies in populations aged ≥ 60
or ≥ 65 years (shown by asterisks). There was no clear
difference in G-CSF effectiveness between cancer types,
nor in studies restricting to an elderly population. As
the majority of studies administered filgrastim and leno-
grastim for 10-14 days (for 3-week chemotherapy
cycles), there was insufficient data to assess the effects
of shorter durations of G-CSF treatment.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant citations 
identified and screened for retrieval: 
     N = 4197 citations 
Citations rejected at title or 
abstract stage: 
     N = 4177 citations 
Total full papers included, from updated search and previous reviews: 
     N = 23 citations relating to 25 studies: 
  Pegfilgrastim vs. no primary G-CSF: 5 RCTs (within 4 citations) 
  Filgrastim vs. no primary G-CSF: 10 RCTs (within 9 citations) 
  Lenograstim vs. no primary G-CSF: 5 RCTs 
  Pegfilgrastim vs. filgrastim: 5 RCTs 
  Pegfilgrastim vs. lenograstim: 0 RCTs 
  Lenograstim vs. filgrastim: 0 RCTs 
Additional studies identified since previous reviews: 
     N = 4 citations relating to 5 studies: 
  Pegfilgrastim vs. no primary G-CSF: 4 additional RCTs 
(within 3 citations) 
  Filgrastim vs. no primary G-CSF: 1 additional RCT (1 citation) 
Citations rejected at full 
text stage: 
     N = 16 citations 
Full texts reviewed: 
     N = 20 citations 
Studies included from previous reviews: 
     N = 19 citations relating to 20 studies 
Figure 1 Flow chart for identification of relevant studies.
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Page 3 of 11Table 1 Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other)
Trial Study
design
Cancer type Cancer
stage
Patient
age
Chemotherapy
regimen
N cycles
(max)
Cycle
length
Arm 1 G-CSF
strategy
b
Arm 1:
N
analysed
Arm 1:
days
primary
G-CSF
Arm 2 G-CSF
strategy
b
Arm 2:
N
analysed
Arm 2:
days
primary
G-CSF
FN
definition
Pegfilgrastim
vs. no
primary
G-CSF
a Romieu 2007
[23]
RCT,
phase
II, OL
Breast
cancer
Stage II-III,
node-
positive
Age ≥
65.
Median
68,
range
65-77
FEC-100 6 (FN
reported
cycle 1
only)
3 weeks Pegfilgrastim
primary: 6 mg day 2
30 1 No primary G-
CSF,
pegfilgrastim
secondary
(following FN
or
neutropenia)
29 0 Fever +
ANC < 1
×1 0
9/l
Vogel 2005[21] RCT,
phase
III, DB
Breast
cancer
62% stage
IV, 38%
other
stages
Mean
age 52,
range
21-88
Docetaxel 100
mg/m
2
4 3 weeks Pegfilgrastim
primary: 6 mg day 2
463 1 Placebo
primary,
pegfilgrastim
secondary
(following FN)
465 0 Fever +
ANC < 0.5
×1 0
9/l
a Hecht 2009
[24]
RCT,
phase
II
Colorectal
cancer
NR NR FOLFOX (49%),
FOLFIRI (26%) or
FOIL (25%)
4 2 weeks Pegfilgrastim
primary: 6 mg day 4
123 1 Placebo
primary
118 0 Grade 3-4
FN
(assumed
fever +
ANC < 1
×1 0
9/l)
a Balducci
2007: NHL[22]
RCT,
OL
NHL 38% stage
I-II, 62%
stage III-IV
Age ≥
65.
Median
72,
range
65-88
CHOP or R-
CHOP
6 3 weeks Pegfilgrastim
primary: 6 mg day 2
73 1 No primary G-
CSF,
pegfilgrastim
secondary (at
physician’s
discretion)
73 0 Fever +
ANC < 1
×1 0
9/l
a Balducci
2007: solid
tumour[22]
RCT,
OL
Solid tumour
(lung,
ovarian,
breast)
31% stage
I-II, 69%
stage III-IV
Age ≥
65.
Median
72,
range
65-88
One of 15
regimens with
mild-to-
moderate risk of
neutropenia
6 3 weeks Pegfilgrastim
primary: 6 mg day 2
343 1 No primary G-
CSF,
pegfilgrastim
secondary (at
physician’s
discretion)
343 0 Fever +
ANC < 1
×1 0
9/l
Filgrastim vs.
no primary
G-CSF
a del Giglio
2008[33]
RCT,
DB
Breast
cancer
21% high-
risk stage
II,
53% stage
III,
25% stage
IV
Mean
age 51,
range
25-75
Doxorubicin 60
mg/m
2/
docetaxel 75
mg/m
2
4 (FN
reported
cycle 1
only)
3 weeks Filgrastim primary
(Neupogen or
XM02): 5 ug/kg/d
from day 2 up to
14d or to ANC = 10
×1 0
9/l
276 5 to 14
(median
9-10)
Placebo in
cycle 1;
filgrastim
(XM02) in
subsequent
cycles
72 0 (cycle
1)
Fever +
ANC < 0.5
×1 0
9/l
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1Table 1 Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other) (Continued)
Timmer-Bonte
2005[29]
RCT,
phase
III, OL
SCLC 69%
extensive,
31%
limited
Age
range
36-81
CDE 5 3 weeks Filgrastim primary:
300/450 ug/d from
day 4; prophylactic
antibiotics
90 10 No primary G-
CSF;
prophylactic
antibiotics
85 0 Fever +
ANC < 0.5
×1 0
9/l
Trillet-Lenoir
1993[30]
RCT,
DB
SCLC 64%
extensive,
36%
limited
Median
59
CDE 6 3 weeks Filgrastim primary:
230 ug/m
2/d from
day 4 up to 14d or
until ANC = 10 ×
10
9/l
65 9 to 14 Placebo
primary
64 0 Fever +
ANC < 1
×1 0
9/l
Crawford 1991
[31]
RCT,
DB
SCLC 72%
extensive,
28%
limited
Age
range
31-80
CDE 6 3 weeks Filgrastim primary:
230 ug/m
2/d from
day 4 up to 14d or
until ANC = 10 ×
10
9/l
95 9 to 14 Placebo
primary;
secondary G-
CSF
104 0 Fever +
ANC < 1
×1 0
9/l
Doorduijn
2003[25]
RCT,
OL
Aggressive
NHL
Stage II-IV Age ≥
65.
Median
72,
range
65-90
CHOP 6 to 8 3 weeks Filgrastim primary:
300 ug/d from day 2
for 10d
197 10 No primary G-
CSF
192 0 FN not
defined in
terms of
ANC
Osby 2003
(CHOP)[26]
RCT,
OL
Aggressive
NHL
Stage II-IV Age ≥
60.
Median
71,
range
60-86
CHOP 4 to 8
(most 8)
3 weeks Filgrastim primary: 5
ug/kg/d from day 2
up to 14d or until
ANC = 10 × 10
9/l
101 10 to 14 No primary G-
CSF
104 0 Fever +
ANC < 0.5
×1 0
9/l
Osby 2003
(CNOP)[26]
RCT,
OL
Aggressive
NHL
Stage II-IV Age ≥
60.
Median
71,
range
60-86
CNOP 4 to 8
(most 8)
3 weeks Filgrastim primary: 5
ug/kg/d from day 2
up to 14d or until
ANC = 10 × 10
9/l
125 10 to 14 No primary G-
CSF
125 0 Fever +
ANC < 0.5
×1 0
9/l
Zinzani 1997
[27]
RCT,
OL
Aggressive
NHL
Stage II-IV Age ≥
60. Age
range
60-82
VNCOP-B 8 1 week
(differs
alternate
weeks)
Filgrastim primary: 5
ug/kg/d from day 3;
prophylactic
antibiotics
77 5 No primary G-
CSF;
prophylactic
antibiotics
72 0 FN not
defined in
terms of
ANC
Pettengell
1992[28]
RCT,
OL
Aggressive
NHL
Any stage Age
range
16-71
VAPEC-B 11 1 week
(differs
alternate
weeks)
Filgrastim primary:
230 ug/m
2/d from
day 2 up to 14d or
until ANC = 10 ×
10
9/l; prophylactic
antibiotics
41 12 No primary G-
CSF;
prophylactic
antibiotics
39 0 Fever +
ANC < 1
×1 0
9/l
Fossa 1998[32] RCT,
phase
III, OL
Germ cell
cancer
Metastatic,
poor-
prognosis
Age
range
15-65
BEP/EP or BOP/
VIP-B
6 3 weeks
or 10 d
Filgrastim primary: 5
ug/kg/d from day 3
or 6
129 7 or 14 No primary G-
CSF
130 0 FN not
defined in
terms of
ANC
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1Table 1 Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other) (Continued)
Lenograstim
vs. no
primary G-
CSF
Chevallier
1995[9]
RCT,
DB
Breast
cancer,
inflammatory
Non-
metastatic
Age
range
23-65
FEC-high-dose 4 3 weeks Lenograstim primary:
5 ug/kg/d from day
6
61 10 Placebo
primary
59 0 Fever +
ANC < 1
×1 0
9/l
Gisselbrecht
1997[34]
RCT,
DB
Aggressive
NHL
Any stage Age
range
15-55
LNH-87 (LNH-84
+ randomization
to
anthracyclines)
4 2 weeks Lenograstim primary:
5 ug/kg/d from day
6
82 8 Placebo
primary
80 0 Fever +
ANC < 1
×1 0
9/l
Bui 1995[10] RCT,
DB
Soft tissue
sarcoma
Metastatic
or locally
advanced
Age
range
21-69
MAID 6 (FN
reported
cycle 1
only)
3 weeks Lenograstim primary:
5 ug/kg/d from day
4 up to 14d or until
ANC = 30 × 10
9/l
22 10 to 14 Placebo
primary;
secondary G-
CSF
26 0 Fever +
ANC < 1
×1 0
9/l
Gebbia 1994
[35]
RCT,
DB
Various Advanced Age
range
40-75
Various Various Various Lenograstim primary:
5 ug/kg/d
23 ≥ 7d Placebo
primary
28 0 Fever +
ANC < 1
×1 0
9/l
Gebbia 1993
[36]
RCT,
DB
Various Advanced Age
range
38-66
Various Various Various Lenograstim primary:
5 ug/kg/d
43 7 to 10 Placebo
primary
43 0 Fever +
ANC < 1
×1 0
9/l
Pegfilgrastim
vs. 10- or 11-
day filgrastim
Green 2003[7] RCT,
phase
III, DB
Breast
cancer
28% stage
II, 27%
stage III,
45% stage
IV
Mean
age 52,
range
30-75
Doxorubicin 60
mg/m
2/
docetaxel 75
mg/m
2
4 3 weeks Pegfilgrastim
primary: 6 mg day 2;
then placebo up to
14d
77 1 Filgrastim
primary: 5 ug/
kg, from day 2
up to 14d or
until ANC = 10
×1 0
9/l
75 11
(median)
Fever +
ANC < 0.5
×1 0
9/l
Holmes 2002:
phase III[8]
RCT,
phase
III, DB
Breast
cancer
High-risk
stage II, III
or IV. 37%
stage IV
Mean
age 51
Doxorubicin 60
mg/m
2/
docetaxel 75
mg/m
2
4 3 weeks Pegfilgrastim
primary: 100 ug/kg
day 2; then placebo
up to 14d
149 1 Filgrastim
primary: 5 ug/
kg, from day 2
up to 14d or
until ANC = 10
×1 0
9/l
147 11
(mean)
Fever +
ANC < 0.5
×1 0
9/l
Holmes 2002:
phase II[37]
RCT,
phase
II, DF
Breast
cancer
High-risk
stage II, III
or IV. 30%
stage IV
Mean
age 49
Doxorubicin 60
mg/m
2/
docetaxel 75
mg/m
2
4 3 weeks Pegfilgrastim
primary: 100 ug/kg
day 2 (other dose
groups not included
here)
46 1 Filgrastim
primary: 5 ug/
kg, from day 2
up to 14d or
until ANC = 10
×1 0
9/l
25 10.6;
10.2;
10.4;
11.0
(mean
in cycles
1-4)
Fever +
ANC < 0.5
×1 0
9/l
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1Table 1 Description of trials of primary G-CSFs (vs. no primary G-CSF, or vs. each other) (Continued)
Grigg 2003[38] RCT,
phase
II, OL,
DF
NHL Any stage Age ≥
60.
Mean
68,
range
60-82
CHOP 6 3 weeks Pegfilgrastim
primary: 100 ug/kg
day 2 (other dose
groups not included
here)
14 1 Filgrastim
primary: 5 ug/
kg, from day 2
up to 14d or
until ANC = 10
×1 0
9/l
13 10
(mean)
Fever +
ANC < 0.5
×1 0
9/l
Vose 2003[39] RCT,
phase
II, OL
NHL (n = 56)
or HL (n =
4)
Relapsed
or
refractory
Mean
age 49.
85% <
65
ESHAP 4 (FN
reported
cycles 1
& 2 only)
3 weeks Pegfilgrastim
primary: 100 ug/kg
day 2
29 1 Filgrastim
primary: 5 ug/
kg, from day 2
up to 12d or
until ANC = 10
×1 0
9/l
31 11
(median)
Fever +
ANC < 0.5
×1 0
9/l
a Studies added as a result of updated search.
b G-CSF strategy: Primary prophylaxis is in all cycles. Secondary prophylaxis is in all cycles following FN, or following FN or neutropenia, or at physician’s discretion (as
noted for individual studies). ANC = absolute neutrophil count; DB = double-blind; DF = dose-finding; HL = Hodgkin’s lymphoma; NHL = non-Hodgkin’s lymphoma; OL = open-label; SCLC = small-cell lung cancer.
Chemotherapy regimens used: BEP/EP = etoposide 100 mg/m
2, cisplatin 20 mg/m
2, plus or minus bleomycin 30 U. BOP/VIP-B = bleomycin 30 U, vincristine 2 mg, cisplatin 20-50 mg/m
2/etoposide 100 mg/m
2,
ifosfamide 1000 mg/m
2. CDE = cyclophosphamide 1 g/m
2, doxorubicin 45-50 mg/m
2, etoposide 100-120 mg/m
2. CHOP = cyclophosphamide 750 mg/m
2, doxorubicin 50 mg/m
2, vincristine 1.4 mg/m
2, prednisolone
100 mg days 1-5. CNOP = cyclophosphamide 750 mg/m
2, mitoxantrone 10 mg/m
2, vincristine 1.4 mg/m
2, prednisolone 50 mg/m
2 days 1-5. ESHAP = etoposide 40 mg/m
2, methylprednisolone 500 mg, cisplatin 25
mg/m
2/d, cytarabine 2000 mg/m
2. FEC-100 = 5-fluorouracil 500 mg/m
2, epirubicin 100 mg/m
2, cyclophosphamide 500 mg/m
2. FEC-high-dose = 5-fluorouracil 750 mg/m
2, epirubicin 35 mg/m
2, cyclophosphamide 400
mg/m
2. FOIL = 5-FU, oxaliplatin, irinotecan, leucovorin. FOLFIRI = 5-FU, irinotecan, leucovorin. FOLFOX = 5-FU, oxaliplatin, leucovorin. LNH-87 = cyclophosphamide 1200 mg/m
2 day 1, vindesine 2 mg/m
2 days 1 & 5,
bleomycin 10 mg days 1 & 5, prednisolone 60 mg/m
2 days 1-5, methotrexate 15 mg, with either doxorubicin 75 mg/m
2 or mitoxantrone 12 mg/m
2 day 1. MAID = mesna, doxorubicin, ifosfamide, dacarbazine. R-
CHOP = CHOP plus rituximab. TAC = doxorubicin 50 mg/m
2, cyclophosphamide 500 mg/m
2, docetaxel 75 mg/m
2. VAPEC-B = vincristine 1.4 mg/m
2, doxorubicin 35 mg/m
2 prednisolone 50 mg/d (then tapered),
etoposide 100 mg/m
2, cyclophosphamide 350 mg/m
2, bleomycin 10 mg/m
2. VNCOP-B = vincristine 2 mg, mitoxantrone 10 mg/m
2, cyclophosphamide 300 mg/m
2, etoposide 150 mg/m
2, prednisone 40 mg,
bleomycin 10 mg/m
2.
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1Figure 2 Primary G-CSFs versus no primary G-CSF: FN incidence. Cancer types for each study are shown after the author and date. CHOP
and CNOP = chemotherapy regimens for NHL (see Table 1 footnote); NHL = non-Hodgkin’s lymphoma; SCLC = small-cell lung cancer; solid =
solid tumours. *Indicates studies in patients aged ≥ 60 or ≥ 65 years.
Figure 3 Pegfilgrastim versus filgrastim: FN incidence. Cancer types for each study are shown after the author and date. HL = Hodgkin’s
lymphoma; NHL = non-Hodgkin’s lymphoma. *Indicates studies in patients aged ≥ 60 or ≥ 65 years. In the Holmes 2002 (phase II) study,[37] FN
incidence in the filgrastim arm was reported as 2/25, which was incorrectly converted to 12%. The absolute numbers (2/25) have been used in
this analysis. Therefore the resulting relative risk differs slightly from that reported in the previous systematic review by Pinto (2007),[19] which
used the 12% figure.
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the relative risk of FN for pegfilgrastim versus filgrastim
was 0.66 (95% CI: 0.44 to 0.98). There were no head-to-
head trials comparing lenograstim to either of the other
two G-CSFs.
Discussion
Our systematic review and meta-analyses confirm and
strengthen previous evidence that primary prophylaxis
with each of the three G-CSFs is effective in reducing
the risk of FN following chemotherapy. In particular,
our systematic review identified 4 further RCTs of peg-
filgrastim vs. no primary G-CSF, [22-24] whereas at the
time of a previous systematic review [18] only a single
RCT [21] making this comparison was available.
Although these 5 RCTs comparing pegfilgrastim with
no primary G-CSF were heterogeneous in terms of clini-
cal population and chemotherapy regimen, the pooled
relative risk indicated a significant effect of pegfilgrastim
in reducing FN incidence. Filgrastim and lenograstim
also significantly reduced FN incidence.
This review also strengthens the evidence base regard-
ing the comparative effectiveness of the three G-CSFs;
in particular, comparison of the “once-per-cycle” G-CSF
pegfilgrastim versus the “once-daily” G-CSF filgrastim.
Meta-analysis of five RCTs indicated that FN incidence
was significantly lower following primary prophylaxis
with pegfilgrastim than with filgrastim. This is consis-
tent with the fact that the reduction in FN risk for peg-
filgrastim versus no primary G-CSF was greater than the
reduction observed for filgrastim versus no primary G-
CSF.
As discussed in previous reviews, [18,19] there was
heterogeneity among the studies in terms of the clinical
population (age, cancer type), chemotherapy regimen,
and cycle length and number. Correspondingly, hetero-
geneity was observed among the study results. Since
individual studies differed on too many variables for for-
mal sub-analyses to be meaningful, all studies were
included in the analysis. There was no clear difference
in G-CSF effectiveness between cancer types, nor in stu-
dies restricting to elderly populations. However, the var-
iation in clinical population, and the corresponding high
levels of heterogeneity, indicate that caution should be
used when applying the results to individual clinical set-
tings. Conversely, the range of populations and treat-
ment regimens covered by the included studies is likely
to reflect the variations which would be observed in
clinical practice.
Conclusions
This systematic review and meta-analysis demonstrate
that primary G-CSF prophylaxis with pegfilgrastim, fil-
grastim and lenograstim is effective in reducing the risk
of FN in adults undergoing chemotherapy for solid
tumours or lymphoma. In addition, although heteroge-
neity existed between studies, a meta-analysis suggests
that pegfilgrastim reduces the risk of FN to a greater
extent than filgrastim.
Appendix 1: Search strategy (Medline)
1 Granulocyte colony-stimulating factor/
2 Granulocyte colony-stimulating factor, recombinant/
3 Colony-stimulating factors, recombinant/
4 Filgrastim/
5 G-CSF$
6 granulocyte colony-stimulating factor$
7 filgrastim
8 Neupogen
9 pegfilgrastim
10 Neulasta
11 lenograstim
12 Granocyte
13 Euprotin
14 r-metHuG-CSF
15 SD-01
16 PEG-rmetHuG-CSF
17 XM02
18 Ratiograstim
19 or/1-18
20 randomized controlled trial.pt.
21 controlled clinical trial.pt.
22 randomized controlled trial/
23 random allocation/
24 double blind method/
25 single blind method/
26 clinical trial.pt.
27 exp clinical trial/
Table 2 Summary of febrile neutropenia incidence based on meta-analyses of trials of G-CSFs
Treatment 1 Treatment 2 No of studies No of patients Relative risk of FN (95% CI) p-value I
2 (heterogeneity)
Pegfilgrastim No primary G-CSF 5 2060 0.30 (0.14 to 0.65) p = 0.002 76%
Filgrastim No primary G-CSF 10 2183 0.57 (0.48 to 0.69) p < 0.00001 50%
Lenograstim No primary G-CSF 5 467 0.62 (0.44 to 0.88) p = 0.007 64%
Any G-CSF No primary G-CSF 20 4710 0.51 (0.41 to 0.62) p < 0.00001 74%
Pegfilgrastim Filgrastim 5 606 0.66 (0.44 to 0.98) p = 0.04 0%
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Page 9 of 1128 (clin$ adj25 trial$).ti,ab.
29 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$
or mask$)).ti,ab.
30 placebos/
31 placebos.ti,ab.
32 random.ti,ab.
33 research design/
34 randomised.ti,ab
35 randomized.ti,ab
36 or/20-35
37 19 and 36
("$” indicates truncations; “/” indicates medical subject
headings)
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